A modified toxicity probability interval method for dose-finding trials

Type: Article

Publication Date: 2010-10-08

Citations: 231

DOI: https://doi.org/10.1177/1740774510382799

Abstract

Background Building on earlier work, the toxicity probability interval (TPI) method, we present a modified TPI (mTPI) design that is calibration-free for phase I trials. Purpose Our goal is to improve the trial conduct and provide more effective designs while maintaining the simplicity of the original TPI design. Methods Like the TPI method, the mTPI consists of a practical dose-finding scheme guided by the posterior inference for a simple Bayesian model. However, the new method proposes improved dose-finding decision rules based on a new statistic, the unit probability mass (UPM). For a given interval and a probability distribution, the UPM is defined as the ratio of the probability mass of the interval to the length of the interval. Results The improvement through the use of the UPM for dose finding is threefold: (1) the mTPI method appears to be safer than the TPI method in that it puts fewer patients on toxic doses; (2) the mTPI method eliminates the need for calibrating two key parameters, which is required in the TPI method and is a known difficult issue; and (3) the mTPI method corresponds to the Bayes rule under a decision theoretic framework and possesses additional desirable large- and small-sample properties. Limitation The proposed method is applicable to dose-finding trials with a binary toxicity endpoint. Conclusion The new method mTPI is essentially calibration free and exhibits improved performance over the TPI method. These features make the mTPI a desirable choice for the design of practical trials. Clinical Trials 2010; 7: 653—663. http://ctj.sagepub.com

Locations

  • PubMed Central - View
  • Europe PMC (PubMed Central) - View - PDF
  • PubMed - View
  • Clinical Trials - View

Similar Works

Action Title Year Authors
+ Abstract 423: Toxicity and efficacy probability intervals design for phase I dose-finding in oncology trials 2016 Daniel H. Li
Jim Whitmore
Yuan Ji
+ Comparison of novel phase I clinical trial designs based on toxicity probability intervals 2017 Yi Yao
+ PDF Chat A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2 2017 Wentian Guo
Sue‐Jane Wang
Shengjie Yang
Henry Lynn
Yuan Ji
+ PDF Chat Performance of toxicity probability interval based designs in contrast to the continual reassessment method 2016 Bethany J. Horton
Nolan A. Wages
Mark R. Conaway
+ Data from Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials 2023 Fangrong Yan
Sumithra J. Mandrekar
Ying Yuan
+ Data from Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials 2023 Fangrong Yan
Sumithra J. Mandrekar
Ying Yuan
+ PDF Chat Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials 2017 Fangrong Yan
Sumithra J. Mandrekar
Ying Yuan
+ Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment 2022 Xin Wei
Rong Liu
+ MTPI: Stata module for the modified Toxicity Probability Interval design 2020 Adrian Mander
+ MTPI: Stata module for the modified Toxicity Probability Interval design 2020 Adrian Mander
+ qTPI: A quasi-toxicity probability interval design for phase I trials with multiple-grade toxicities 2023 H. Ling
Haolun Shi
Nan Yuan
Yuan Ji
Xiaolei Lin
+ Dose-finding in phase I clinical trials based on toxicity probability intervals 2007 Yuan Ji
Yisheng Li
B. Nebiyou Bekele
+ Comparative review of novel model‐assisted designs for phase I clinical trials 2018 Heng Zhou
Thomas A. Murray
Haitao Pan
Ying Yuan
+ PDF Chat A hybrid design for dose‐finding oncology clinical trials 2022 Jason J. Z. Liao
Feng Zhou
Heng Zhou
Lilli Petruzzelli
Kevin Hou
Ekaterine Asatiani
+ PDF Chat Target toxicity design for phase I dose-finding 2020 Wenchuan Guo
Bob Zhong
+ Target toxicity design for phase I dose-finding 2021 Wenchuan Guo
Bob Zhong
+ Data from Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials 2023 Ying Yuan
Kenneth R. Hess
Susan G. Hilsenbeck
Mark R. Gilbert
+ Data from Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials 2023 Ying Yuan
Kenneth R. Hess
Susan G. Hilsenbeck
Mark R. Gilbert
+ Introduction to Phase I Dose-Finding Clinical Trials 2023 Haitao Pan
Ying Yuan
+ A Unified Decision Framework for Phase I Dose-Finding Designs 2021 Yunshan Duan
Shijie Yuan
Yuan Ji
Peter P. Mueller